Metabolic Mechanisms in Heart Failure
Top Cited Papers
- 24 July 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 116 (4), 434-448
- https://doi.org/10.1161/circulationaha.107.702795
Abstract
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the residual disability and death rate remains unacceptably high. Though abnormalities of myocardial metabolism are associated with heart failure, recent data suggest that heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation. A detrimental self-perpetuating cycle (heart failure → altered metabolism → heart failure) that promotes the progression of heart failure may thus be postulated. Accordingly, we review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure. It is hypothesized that the ensuing detrimental myocardial energetic perturbations result from neurohumoral activation, increased adverse free fatty acid metabolism, decreased protective glucose metabolism, and in some cases insulin resistance. The result is depletion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical work. On the basis of the mechanisms outlined, appropriate therapies to mitigate aberrant metabolism include intense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet. We also discuss more novel mechanistic-based therapies to ameliorate metabolism and insulin resistance in heart failure. For example, metabolic modulators may optimize myocardial substrate utilization to improve cardiac function and exercise performance beyond standard care. The ultimate success of metabolic-based therapy will be manifest by its capacity further to lessen the residual mortality in heart failure.Keywords
This publication has 100 references indexed in Scilit:
- Myocardial Glucose Transport and Utilization in Patients With Type 2 Diabetes Mellitus, Left Ventricular Dysfunction, and Coronary Artery DiseaseJournal of the American College of Cardiology, 2006
- Statins in the treatment of chronic heart failure: Biological and clinical considerationsCardiovascular Research, 2006
- Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1αProceedings of the National Academy of Sciences, 2006
- Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function and morphology in db/db miceBiochemical and Biophysical Research Communications, 2006
- Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery diseaseEuropean Heart Journal, 2004
- Genetic manipulation of myocardial ?-adrenergic receptor activation and desensitizationJournal of Molecular and Cellular Cardiology, 2004
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST–segment elevation myocardial infarction: Appropriate interpretation of the guidelinesAmerican Heart Journal, 2003
- Cardiac resynchronization therapyhomogenizes myocardial glucosemetabolism and perfusion in dilatedcardiomyopathy and left bundle branch blockJournal of the American College of Cardiology, 2003
- Adrenaline-induced “oxygen-wastage” and enzyme release from working rat heart. Effects of calcium antagonism, β-blockade, nicotinic acid and coronary artery ligationJournal of Molecular and Cellular Cardiology, 1979
- Fatty Acid and Glucose Metabolism in the Perfused HeartNature, 1961